M
Michael A. Acker
Researcher at University of Pennsylvania
Publications - 313
Citations - 15649
Michael A. Acker is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Heart failure & Ventricular assist device. The author has an hindex of 57, co-authored 303 publications receiving 13710 citations. Previous affiliations of Michael A. Acker include Johns Hopkins University School of Medicine & Brown University.
Papers
More filters
Journal ArticleDOI
Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation
Robert E. Michler,Peter K. Smith,Michael K. Parides,Gorav Ailawadi,Vinod H. Thourani,Alan J. Moskowitz,Michael A. Acker,Judy Hung,Helena L. Chang,Louis P. Perrault,A. Marc Gillinov,Michael Argenziano,Emilia Bagiella,Jessica Overbey,Ellen Moquete,Lopa N. Gupta,Marissa A. Miller,Wendy C. Taddei-Peters,Neal Jeffries,Richard D. Weisel,Eric A. Rose,James S. Gammie,James S. Gammie,Joseph J. DeRose,John D. Puskas,François Dagenais,Sandra G. Burks,Ismail El-Hamamsy,Carmelo A. Milano,Pavan Atluri,Pierre Voisine,Patrick T. O'Gara,Annetine C. Gelijns +32 more
TL;DR: Mitral-valve repair provided a more durable correction of mitral regurgitation but did not significantly improve survival or reduce overall adverse events or readmissions and was associated with an early hazard of increased neurologic events and supraventricular arrhythmias.
Journal ArticleDOI
Mitral-Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation
Michael A. Acker,Michael K. Parides,Louis P. Perrault,Alan J. Moskowitz,Annetine C. Gelijns,Pierre Voisine,Peter K. Smith,Judy Hung,Eugene H. Blackstone,John D. Puskas,Michael Argenziano,James S. Gammie,Michael J. Mack,Deborah D. Ascheim,Emilia Bagiella,Ellen Moquete,T. Bruce Ferguson,Keith A. Horvath,Nancy L. Geller,Marissa A. Miller,Y. Joseph Woo,David A. D'Alessandro,Gorav Ailawadi,François Dagenais,Timothy J. Gardner,Patrick T. O'Gara,Robert E. Michler,Irving L. Kron +27 more
TL;DR: Replacement provided a more durable correction of mitral regurgitation, but there was no significant between-group difference in clinical outcomes.
Journal ArticleDOI
Unexpected Abrupt Increase in Left Ventricular Assist Device Thrombosis
Randall C. Starling,Nader Moazami,Scott C. Silvestry,Gregory A. Ewald,Joseph G. Rogers,Carmelo A. Milano,J. Eduardo Rame,Michael A. Acker,Eugene H. Blackstone,John Ehrlinger,Lucy Thuita,Maria Mountis,Edward G. Soltesz,Bruce W. Lytle,Nicholas G. Smedira +14 more
TL;DR: The rate of pump thrombosis related to the use of the HeartMate II has been increasing at centers and is associated with substantial morbidity and mortality.
Journal ArticleDOI
Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation 5-Year Results of EVEREST II
Ted Feldman,Saibal Kar,Sammy Elmariah,Steven C. Smart,Alfredo Trento,Robert J. Siegel,Patricia Apruzzese,Peter S. Fail,Michael Rinaldi,Richard W. Smalling,James B. Hermiller,David Heimansohn,William A. Gray,Paul A. Grayburn,Michael J. Mack,D. Scott Lim,Gorav Ailawadi,Howard C. Herrmann,Michael A. Acker,Frank E. Silvestry,Elyse Foster,Andrew Wang,Donald D. Glower,Laura Mauri,Everest Investigators +24 more
TL;DR: Patients treated with percutaneous repair more commonly required surgery for residual MR during the first year after treatment, but between 1- and 5-year follow-up, comparably low rates of surgery for MV dysfunction with either per cutaneous or surgical therapy endorse the durability of MR reduction with both repair techniques.
Journal ArticleDOI
Use of an Intrapericardial, Continuous-Flow, Centrifugal Pump in Patients Awaiting Heart Transplantation
Keith D. Aaronson,Mark S. Slaughter,Leslie W. Miller,Edwin C. McGee,William Cotts,Michael A. Acker,Mariell Jessup,Igor D. Gregoric,Pranav Loyalka,O.H. Frazier,Valluvan Jeevanandam,Allen S. Anderson,Robert L. Kormos,Jeffrey J. Teuteberg,Wayne C. Levy,D.C. Naftel,Richard M. Bittman,Francis D. Pagani,David R. Hathaway,Steven W. Boyce +19 more
TL;DR: A small, intrapericardially positioned, continuous-flow, centrifugal pump was noninferior to contemporaneously implanted, commercially available ventricular assist devices and functional capacity and quality of life improved markedly, and the adverse event profile was favorable.